Vivasor, Inc.
22 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Oct 2032
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 13, 2027The maintenance fee for Antigen Binding Proteins That Bind C-Met (US 10,377,827) comes due Feb 13, 2027. Unpaid by Aug 13, 2027, it lapses early.
- 2 fees due Mar 5 to 19, 2027 · next Mar 5
- 1 fee due Apr 3, 2027The maintenance fee for Variant Antibodies That Bind OX40 (US 11,773,177) comes due Apr 3, 2027. Unpaid by Oct 4, 2027, it lapses early.
- 3 fees due May 3 to 19, 2027 · next May 3
- 1 fee due Jun 30, 2027The maintenance fee for Antibodies Which Bind Insulin-Like Growth Factor Receptor-1 (IGF1R) and Methods of Use Thereof to Treat Cancer (US 10,519,245) comes due Jun 30, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 1 fee due Sep 17, 2027The maintenance fee for Antibody Drug Conjugates (US 10,590,165) comes due Sep 17, 2027. Unpaid by Mar 17, 2028, it lapses early.
- 1 fee due Oct 19, 2027The maintenance fee for Antigen Binding Proteins That Bind CCR2 (US 9,315,579) comes due Oct 19, 2027. Unpaid by Apr 19, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,213,588 | Transdermal Delivery of High Viscosity Bioactive Agents In force · Medium confidence | In force | Medium confidence | |
| US 9,550,053 | Transdermal Delivery of High Viscosity Bioactive Agents In force · High confidence | In force | High confidence | |
| US 10,773,065 | Increased Bioavailability of Transdermally Delivered Agents In force · Medium confidence | In force | Medium confidence | |
| US 9,029,510 | Fully Human Antibodies that Bind to VEGFR2 and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 10,174,107 | Antigen Binding Proteins that Bind Delta-Like 4 (DLL-4) In force · High confidence | In force | High confidence | |
| US 10,717,779 | Methods for Blocking an Interaction Between NOTCH-1 and Delta-Like 4 (DLL-4) by Administering a DDL-4 Antibody In force · High confidence | In force | High confidence | |
| US 10,058,609 | Antigen Binding Proteins That Bind PD-L1 In force · Medium confidence | In force | Medium confidence | |
| US 9,884,127 | Drug-Conjugates, Conjugation Methods, and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,115,228 | Drug-Conjugates, Conjugation Methods, And Uses Thereof In force · Low confidence | In force | Low confidence | |
| US 10,519,245 | Antibodies Which Bind Insulin-Like Growth Factor Receptor-1 (IGF1R) and Methods of Use Thereof to Treat Cancer In force · High confidence | In force | High confidence |
Also on record, not counted in the 44: 22 patents in force now held by others · 16 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 1 no status recorded